Pfizer's Talzenna/Xtandi Combo Receives FDA Priority Review for Prostate Cancer
The FDA has granted priority review to Pfizer’s supplemental New Drug Application (sNDA) for combining Talzenna and Xtandi in treating metastatic prostate cancer. The decision date is set for Q4, which could accelerate regulatory approval.
Tickers: $PFE